Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs. - Wikidata - awgldk - TriplyDB

Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs.

Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs.

http://www.wikidata.org/entity/Q37656225

about

Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer Paclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatment New developments in treatment of ovarian carcinoma: focus on trabectedin Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence.Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study Synthetic paclitaxel-octreotide conjugate reversing the resistance of A2780/Taxol to paclitaxel in xenografted tumor in nude mice.The critical role of HMGA2 in regulation of EMT in epithelial ovarian carcinomas.Knockdown of Eag1 Expression by RNA Interference Increases Chemosensitivity to Cisplatin in Ovarian Cancer Cells.CXCR7 signaling induced epithelial-mesenchymal transition by AKT and ERK pathways in epithelial ovarian carcinomas.Crk-like adapter protein is required for TGF-β-induced AKT and ERK-signaling pathway in epithelial ovarian carcinomas.Clinicopathological impact of ABCC1/MRP1 and ABCC4/MRP4 in epithelial ovarian carcinoma.Optimizing treatment in recurrent epithelial ovarian cancer.Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study.A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor mo

P2860

Q24234736-0F96F51E-09B2-41C5-9131-0100791C34C3 Q28073057-CABBBCBB-2FA4-4E78-A2D5-21892BCAEFF0 Q33393429-1A2B67BC-DED5-4EE4-A8E1-DAE727CECF91 Q33921802-B6E92AC0-8128-460D-9498-03D6A11381C4 Q34993605-A76C19C1-2047-4742-B10B-B74822CE9A28 Q37696327-EF3ABAF0-84C3-4158-976C-7676E07EAFA3 Q38845718-79963460-0BD7-4A47-8798-95A7182B1932 Q38863540-166CE3EB-0A36-4FD4-B587-791494DC6C0F Q38943635-B407EAB9-A76E-4B31-97A9-437256AF4C94 Q38948674-2145FD27-2EC5-4227-8BD9-D738C058AAC6 Q41811277-188F2C4A-0654-40EA-8494-52F042BD2CFE Q47549019-B98F7E9B-F9FE-432E-90D9-821BC51C2D58 Q52603413-DED0AD47-2872-496E-AA4D-4138440F4D0E Q54526385-F1D31718-A3FB-49DC-8D38-9EDD89E7BD8A

P2860

Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs.

http://www.wikidata.org/entity/Q37656225

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs.

@en

Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs.

@nl

type

label

Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs.

@en

Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs.

@nl

prefLabel

Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs.

@en

Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs.

@nl

P1433

Q37656225-860A7A1F-AF70-470E-97D8-BC5F7FEE5AE3

P1476

Q37656225-A66CBB72-E7FC-47FB-856B-17B7DA1BA09D

P2093

Q37656225-477564D3-21EC-4D27-9261-78D1B85E6887

Q37656225-63F2B441-D0F3-4B81-B052-EE7C00B52463

Q37656225-7B2AB7A4-E837-49B1-BE72-B125A9704F4A

Q37656225-AA7E4AC8-1034-4BC6-8349-1D5538290D27

Q37656225-F0CDCFBD-CAC6-48A9-81AA-3E8AED9F0DDA

P2860

Q37656225-0A3744D5-3154-4883-B1F1-15090225F1F9

Q37656225-12F30C7B-E91C-4B8A-ACF0-62C570EB606F

Q37656225-27391D31-3378-4504-9F36-7A078CDAA023

Q37656225-285480A4-EA1B-4A0F-B000-0B23B561FE73

Q37656225-2AA0C4D9-9C25-4390-A202-CD9EE014A380

Q37656225-2AAACFE6-AE47-4066-8DFB-381500E4433D

Q37656225-3A45F288-F1BB-4911-ABD9-49282FC30CDC

Q37656225-3CDE7FBB-16F2-4514-8F05-5867C78099B5

Q37656225-3E24B99E-A82A-4BEB-A479-EE1417BBD87E

Q37656225-3EDC68C6-AD74-482F-B48D-12A6BD212799

P304

Q37656225-11879CE5-D56B-4924-8A89-BA2C72B333D3

P31

Q37656225-7F43D6E7-4365-4BAA-95B8-07D0E85BB340

P356

Q37656225-9B8155E3-F02A-400D-9954-CC15C6CB6179

P433

Q37656225-FD6D3649-E797-49D6-8BB8-8C595FC78AEC

P478

Q37656225-DF25BE3A-EF2D-4A8E-AF08-387FB08B8092

P50

Q37656225-9FE7B6CD-E23D-4CF5-9C60-3933AB24F8F8

P577

Q37656225-033A4981-D136-4824-A65C-50F0CCE1086A

P698

Q37656225-122DD9BE-0049-419A-B0E7-83914FB64639

P921

Q37656225-C5277BFC-C86C-4A8C-992F-0C78B6132847

P356

P1433

Expert Review of Anticancer Therapy

P1476

Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs

@en

P2093

Andreas du Bois

http://www.w3.org/2001/XMLSchema#string

Felix Hilpert

http://www.w3.org/2001/XMLSchema#string

Jacobus Pfisterer

http://www.w3.org/2001/XMLSchema#string

Philipp Harter

http://www.w3.org/2001/XMLSchema#string

Sven Mahner

http://www.w3.org/2001/XMLSchema#string

P2860

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Role of cytoreductive surgery in recurrent ovarian cancer.

Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer--a dose-finding study by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group.

Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (A

Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.

Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer.

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

P304

81-88

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERA.09.165

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20014888

http://www.w3.org/2001/XMLSchema#string

P921